Checkpoint inhibitors for treating cancer is
a type of drug that blocks certain proteins made by some types of immune system
cells, such as T cells, and some cancer cells. These proteins help keep immune
responses in check and can keep T cells from killing cancer cells. When these
proteins are blocked, the “brakes” on the immune system are released and T
cells are able to kill cancer cells better. Examples of checkpoint proteins
found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Scope of the Report:
This report focuses on the Checkpoint Inhibitors for Treating Cancer in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
This report focuses on the Checkpoint Inhibitors for Treating Cancer in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Request
For Sample Report @ https://www.wiseguyreports.com/sample-request/813341-global-checkpoint-inhibitors-for-forecast-to-2021
Market Segment by Manufacturers, this report
covers
Bristol-Myers Squibb(BMS)
Merck
Roche
Bristol-Myers Squibb(BMS)
Merck
Roche
Market Segment by Regions, regional analysis
covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa
Market Segment by Type, covers
PD-1 inhibitors
PD-L1 inhibitors
CTLA-4 inhibitors
PD-1 inhibitors
PD-L1 inhibitors
CTLA-4 inhibitors
Market Segment by Applications, can be
divided into
Melanoma treatment
Bladder cancer treatment
Other
Melanoma treatment
Bladder cancer treatment
Other
There are 13 Chapters to deeply display the
global Checkpoint Inhibitors for Treating Cancer market.
Chapter 1, to describe Checkpoint Inhibitors
for Treating Cancer Introduction, product scope, market overview, market
opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers
of Checkpoint Inhibitors for Treating Cancer, with sales, revenue, and price of
Checkpoint Inhibitors for Treating Cancer, in 2015 and 2016;
Chapter 3, to display the competitive
situation among the top manufacturers, with sales, revenue and market share in
2015 and 2016;
Chapter 4, to show the global market by
regions, with sales, revenue and market share of Checkpoint Inhibitors for
Treating Cancer, for each region, from 2011 to 2016;
Chapter 5, 6, 7 and 8, to analyze the key
regions, with sales, revenue and market share by key countries in these
regions;
Chapter 9 and 10, to show the market by type
and application, with sales market share and growth rate by type, application,
from 2011 to 2016;
Chapter 11, Checkpoint Inhibitors for
Treating Cancer market forecast, by regions, type and application, with sales
and revenue, from 2016 to 2021;
Chapter 12 and 13, to describe Checkpoint
Inhibitors for Treating Cancer sales channel, distributors, traders, dealers,
appendix and data source.
Complete
Report Details @ https://www.wiseguyreports.com/reports/813341-global-checkpoint-inhibitors-for-forecast-to-2021
Table of Contents
Global Checkpoint Inhibitors for Treating
Cancer Market by Manufacturers, Regions, Type and Application, Forecast to 2021
1 Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Introduction
1.2 Market Analysis by Type
1.2.1 PD-1 inhibitors
1.2.2 PD-L1 inhibitors
1.2.3 CTLA-4 inhibitors
1.3 Market Analysis by Applications
1.3.1 Melanoma treatment
1.3.2 Bladder cancer treatment
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA
1.4.1.2 Canada
1.4.1.3 Mexico
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany
1.4.2.2 France
1.4.2.3 UK
1.4.2.4 Russia
1.4.2.5 Italy
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China
1.4.3.2 Japan
1.4.3.3 Korea
1.4.3.4 India
1.4.3.5 Southeast Asia
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil
1.4.4.2 Egypt
1.4.4.3 Saudi Arabia
1.4.4.4 South Africa
1.4.4.5 Nigeria
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb(BMS)
2.1.1 Business Overview
2.1.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
2.2 Merck
2.2.1 Business Overview
2.2.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
2.3 Roche
2.3.1 Business Overview
2.3.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
3 Global Checkpoint Inhibitors for Treating Cancer Market Competition, by Manufacturer
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Manufacturer
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share
3.3.2 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share
3.4 Market Competition Trend
4 Global Checkpoint Inhibitors for Treating Cancer Market Analysis by Regions
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2011-2016)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2011-2016)
4.2 North America Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.5 South America Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5 North America Checkpoint Inhibitors for Treating Cancer by Countries
5.1 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries
5.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2011-2016)
5.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2011-2016)
5.2 USA Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5.3 Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5.4 Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
1 Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Introduction
1.2 Market Analysis by Type
1.2.1 PD-1 inhibitors
1.2.2 PD-L1 inhibitors
1.2.3 CTLA-4 inhibitors
1.3 Market Analysis by Applications
1.3.1 Melanoma treatment
1.3.2 Bladder cancer treatment
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA
1.4.1.2 Canada
1.4.1.3 Mexico
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany
1.4.2.2 France
1.4.2.3 UK
1.4.2.4 Russia
1.4.2.5 Italy
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China
1.4.3.2 Japan
1.4.3.3 Korea
1.4.3.4 India
1.4.3.5 Southeast Asia
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil
1.4.4.2 Egypt
1.4.4.3 Saudi Arabia
1.4.4.4 South Africa
1.4.4.5 Nigeria
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb(BMS)
2.1.1 Business Overview
2.1.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
2.2 Merck
2.2.1 Business Overview
2.2.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
2.3 Roche
2.3.1 Business Overview
2.3.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share
3 Global Checkpoint Inhibitors for Treating Cancer Market Competition, by Manufacturer
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Manufacturer
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share
3.3.2 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share
3.4 Market Competition Trend
4 Global Checkpoint Inhibitors for Treating Cancer Market Analysis by Regions
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2011-2016)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2011-2016)
4.2 North America Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.5 South America Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
4.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5 North America Checkpoint Inhibitors for Treating Cancer by Countries
5.1 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Countries
5.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2011-2016)
5.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2011-2016)
5.2 USA Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5.3 Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
5.4 Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth (2011-2016)
Continued…….
CONTACT
US:
NORAH
TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment